Here’s how analysts see Amedisys, Inc. (NASDAQ:AMED) after this past week.

Amedisys, Inc. (NASDAQ:AMED) Logo
Investors sentiment decreased to 1.03 in Q2 2019. Its down 0.03, from 1.06 in 2019Q1. It dived, as 44 investors sold Amedisys, Inc. shares while 81 reduced holdings. 47 funds opened positions while 82 raised stakes. 26.15 million shares or 1.54% less from 26.55 million shares in 2019Q1 were reported.
Pillar Pacific Limited Liability holds 5,850 shares. Susquehanna Gru Limited Liability Partnership holds 0% or 10,711 shares in its portfolio. Oakbrook Investments Ltd Limited Liability Company owns 2,100 shares. Tower Research Capital Ltd (Trc) reported 2,141 shares. Meeder Asset Mgmt has invested 0% in Amedisys, Inc. (NASDAQ:AMED). Segall Bryant & Hamill Ltd Limited Liability Company accumulated 12,092 shares or 0.02% of the stock. Tudor Et Al owns 10,217 shares for 0.04% of their portfolio. 261,108 are owned by Nuveen Asset Mgmt Limited. 17,966 are held by Bankshares Of Montreal Can. 26,387 were reported by Citigroup. Tompkins Financial Corp reported 303 shares or 0.01% of all its holdings. Moreover, Next has 0.01% invested in Amedisys, Inc. (NASDAQ:AMED) for 676 shares. Fdx Advisors owns 0.03% invested in Amedisys, Inc. (NASDAQ:AMED) for 5,345 shares. Thrivent For Lutherans stated it has 7,701 shares. Carroll Financial Assocs Inc reported 80 shares.

Amedisys, Inc. (NASDAQ:AMED) Ratings Coverage

Among 3 analysts covering Amedisys (NASDAQ:AMED), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Amedisys has $145 highest and $120 lowest target. $138’s average target is 3.95% above currents $132.75 stock price. Amedisys had 7 analyst reports since March 19, 2019 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, July 15 by Raymond James. The rating was maintained by SunTrust on Thursday, March 21 with “Buy”. Raymond James upgraded Amedisys, Inc. (NASDAQ:AMED) rating on Thursday, May 2. Raymond James has “Outperform” rating and $14000 target. On Monday, August 5 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The rating was maintained by Barclays Capital with “Equal-Weight” on Thursday, March 21. Below is a list of Amedisys, Inc. (NASDAQ:AMED) latest ratings and price target changes.

05/08/2019 Broker: Barclays Capital Rating: Equal-Weight Old Target: $120.0000 New Target: $125.0000 Maintain
15/07/2019 Broker: Raymond James Rating: Outperform Old Target: $140.0000 New Target: $144.0000 Maintain
06/06/2019 Broker: BidaskScore Rating: Hold Upgrade
02/05/2019 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform New Target: $140.0000 Upgrade
21/03/2019 Broker: SunTrust Rating: Buy New Target: $145 Maintain
21/03/2019 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $115 New Target: $120 Maintain
19/03/2019 Broker: Oppenheimer Rating: Buy Maintain

The stock increased 0.84% or $1.1 during the last trading session, reaching $132.75. About 207,498 shares traded. Amedisys, Inc. (NASDAQ:AMED) has risen 47.57% since September 13, 2018 and is uptrending. It has outperformed by 47.57% the S&P500.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $4.27 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 35.2 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

More notable recent Amedisys, Inc. (NASDAQ:AMED) news were published by: which released: “Edwards Lifesciences Sapien 3 System Recall Classified Class I – Nasdaq” on August 23, 2019, also with their article: “Medtronic’s (MDT) IN.PACT AV Access Study Results Bode Well – Nasdaq” published on September 10, 2019, published: “Here’s Why You Should Hold on to Hill-Rom (HRC) Stock Now – Nasdaq” on September 04, 2019. More interesting news about Amedisys, Inc. (NASDAQ:AMED) were released by: and their article: “Why Amedisys, Inc.’s (NASDAQ:AMED) High P/E Ratio Isn’t Necessarily A Bad Thing – Yahoo Finance” published on August 20, 2019 as well as‘s news article titled: “Here’s Why You Should Consider Betting on CONMED Stock Now – Nasdaq” with publication date: September 02, 2019.

Amedisys, Inc. (NASDAQ:AMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.